Skip to main content
BDTX logo

Black Diamond Therapeutics, Inc.

BDTXNASDAQHealthcareBiotechnology

$1.75Today:- (-)1Y −46.39%

As of Oct 27, 2026 close

Market cap
$100.39M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.60$4.94
Volume (live)
-
Avg. volume (3M)
810.67K

Black Diamond Therapeutics (BDTX) Income Statement

Black Diamond Therapeutics reported revenue of $70.00M in fiscal 2025 (fiscal year ended Dec 31, 2025). Net income was $22.37M, a net margin of 32.0%. Gross margin was 99.5% and operating margin 28.4%.

Black Diamond Therapeutics Income Statement Analysis

Values in millions USD

Scroll to see more
Black Diamond Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue70.000.000.000.000.000.000.000.000.00
Cost of Revenue0.330.000.440.000.000.600.050.040.02
Gross Profit69.680.00-0.440.000.00-0.60-0.05-0.04-0.02
Operating Expenses
Research & Development33.5651.3159.3564.4496.8348.2121.756.953.45
Selling, General & Administrative16.5727.4727.1128.3930.0421.367.581.950.67
Operating Expenses50.1378.7886.4692.83126.8769.5729.338.904.12
Operating Income19.87-78.78-86.46-92.83-126.87-69.57-8.90-8.90-4.12
Other Income/Expense
Interest Income4.062.181.922.033.464.040.460.000.00
Interest Expense0.000.000.000.000.000.000.000.000.07
Other Income/Expense-1.569.114.02-0.371.282.32-5.93-0.03-0.48
Income
Income Before Tax22.37-69.68-82.44-91.17-125.60-67.25-35.26-8.93-4.60
Income Tax Expense0.000.000.000.000.000.000.00-0.030.00
Net Income22.37-69.68-82.44-91.17-125.60-67.25-35.26-8.93-4.60
Net Income - Continuous Operations22.37-69.68-82.44-91.17-125.60-67.25-35.26-8.93-4.60
Net Income - Discontinued Operations---------
EBITDA20.20-78.44-86.02-92.32-126.67-69.52-29.29-8.89-4.10
EBIT19.87-78.78-86.46-92.83-126.87-69.57---
Depreciation & Amortization0.330.340.440.510.210.050.050.040.02
Earnings Per Share
Basic EPS--1.00-2.00-3.00-3.00-2.00-1.00-1.00-1.00
Diluted EPS--1.00-2.00-3.00-3.00-2.00-1.00-1.00-1.00
Basic Shares Outstanding56.8755.0343.9536.2336.1932.9135.9113.957.20
Diluted Shares Outstanding57.5655.0343.9536.2336.1932.9135.9113.957.20

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Black Diamond Therapeutics Financial Statements

What was Black Diamond Therapeutics's revenue in fiscal 2025?

Black Diamond Therapeutics reported revenue of $70.00M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Is Black Diamond Therapeutics profitable?

Yes. Black Diamond Therapeutics earned net income of $22.37M in fiscal 2025, a net margin of 32.0%. In fiscal 2024 it lost $69.68M.

What is Black Diamond Therapeutics's operating margin?

Black Diamond Therapeutics's operating income was $19.87M on revenue of $70.00M in fiscal 2025, an operating margin of 28.4%.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition